BPGbio, Inc. named in Genetic Engineering & Biotechnology News article “Ten Companies to Watch in AI Drug Discovery” by Alex Philippidis on November 29, 2024! đź“°
The article discusses investment in AI-based drug discovery and the ten companies “…making real progress toward improved therapies”.
BPGbio, Inc. is one of the ten companies!
BPGbio, Inc.‘s own President & CEO, Niven R Narain, Ph.D. is quoted extensively.
From the article:
Big investments in artificial intelligence (AI) don’t guarantee big wins. This point was emphasized by Niven R. Narain, the president and CEO of BPGbio president and CEO Niven R. Narain, PhD, in an editorial he wrote for Forbes. After noting that there has been a cumulative investment of $60 billion in AI-driven drug development, Narain offered a sobering analogy. He suggested that a drug developer employing AI might fail to introduce blockbuster drugs, just as a soccer club fielding superstar Lionel Messi might fail to score game-winning goals.
“The problem isn’t AI itself—it’s the approach most companies have taken to its use,” Narain continued. “The underlying issue for pharma companies using AI lies in the quality of the inputs and how AI models are used. Think of AI as the teamwork and coaching that enable players to reach their full potential.”
Full article (on GEN website): Ten Companies to Watch in AI Drug Discovery
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact:
media@bpgbio.com
